AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03789058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
Study NCT00059813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00059813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03343262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ta-VNS
Description: The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
Study NCT01872858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin, 100mg, Q.D, p.o, 2yr
Study NCT01872858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol, 100mg, B.I.D, p.o, 2yr
Study NCT02085005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02085005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept AVE0005
Description: Pharmaceutical form:concentrate for infusion Route of administration: intravenous
Study NCT03343262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro-acupuncture
Description: one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
Study NCT03343262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
Study NCT02085005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin SR96669
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study NCT01255358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)
Study NCT04011150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural infusion pump
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT04011150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural infusion pump
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT04011150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT04011150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT01787188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules
Study NCT04011150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT01787188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Study NCT03585868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beverage with no flavonoids
Study NCT03585868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavonoids
Description: Flavonoids-enriched cacao beverage
Study NCT03585868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: No Flavonoids
Description: Beverage with alkalinized cocoa which eliminates flavonoid content
Study NCT01398982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine (study group)
Description: At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
Study NCT01398982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline (control group)
Description: At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
Study NCT01398982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline (control group)
Description: At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
Study NCT04011150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT00530439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Dietician counselling and physical training
Study NCT00530439 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Repeated measuring of maternal weight gain, blood samples and ultrasound
Study NCT00530439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity, dietetic counselling
Description: The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
Study NCT02792582 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Therapy
Description: The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
Study NCT02792582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
Study NCT06636435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBA-1205
Description: CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)
Study NCT06636435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBA-1205
Description: CBA-1205 : 20 mg/kg and 30 mg/kg (Intravenous solution)
Study NCT06636435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBA-1205
Description: CBA-1205: 30 mg/kg (Intravenous solution)
Study NCT01314222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BMS-954561
Study NCT01314222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Study NCT01314222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching BMS-954561
Study NCT01314222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Pregabalin
Study NCT04833452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy
Description: Endoscopic DCR
Study NCT02134769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bionecteur
Description: Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
Study NCT01987258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Walking
Study NCT01987258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous walking
Study NCT01101581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veltuzumab and 90Y-Epratuzumab Tetraxetan
Description: Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).
Study NCT01101581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan
Study NCT01101581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
Study NCT03435822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: asthma action plan management group
Description: Patients will follow the directions in asthma action plan when their asthma get worse.
Study NCT03435822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional management group
Description: Patients will follow the directions in conventional strategy when their asthma get worse.
Study NCT03016104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study NCT03016104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
Study NCT03016104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study NCT03016104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study NCT04621097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field
Description: it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
Study NCT04621097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill training
Description: supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
Study NCT04621097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medication
Description: regular medications
Study NCT00471185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
Study NCT03291678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new laparoscopic orchiopexy
Description: closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
Study NCT03291678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic laparoscopic orchiopexy
Description: delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
Study NCT00420355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: Atazanavir 300 mg daily on Days 6-12.
Study NCT00420355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
Study NCT00246441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: 16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
Study NCT00246441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
Study NCT04659837 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No-Added-Sugar Diet
Description: All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
Study NCT04659837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No-Added-Sugar Diet
Description: All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
Study NCT02962739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg/tenofovir alafenamide 25mg
Description: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
Study NCT00293540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oophorectomy
Description: Excision of an ovary
Study NCT00293540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg orally every day
Study NCT03516916 — intervention group
Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
Study NCT02256059 — intervention group
Intervention type: PROCEDURE
Intervention: Plate osteosynthesis
Description: Plate osteosynthesis using LCP plate (Synthes)
Study NCT06703346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Letetresgene autoleucel
Description: Drug: Letetresgene autoleucel Letetresgene autoleucel will be administered. Drug: Cyclophosphamide Cyclophosphamide will be used as a lymphodepleting chemotherapy. Drug: Fludarabine Fludarabine will be used as a lymphodepleting chemotherapy.
Study NCT00874757 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin
Description: Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
Study NCT03143205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARENESS for Sexual Minorities
Description: 9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
Study NCT03143205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing tasks
Description: Writing sessions to explore daily activities.
Study NCT01343056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office Staff Support
Description: The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
Study NCT01343056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support
Description: Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
Study NCT01343056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Support
Description: Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
Study NCT01343056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educator Support
Description: Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
Study NCT04606953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT-II)
Description: The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
Study NCT01285375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CDC solution
Description: 2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
Study NCT01285375 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: UW-solution
Description: 500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
Study NCT06113263 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior cervical decompression surgery
Description: The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
Study NCT06113263 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior cervical foraminotomy with or without laminectomy
Description: The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
Study NCT04188405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT04188405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study NCT04188405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03319693 — intervention group
Intervention type: GENETIC
Intervention: Somatic Genetic
Description: NGS analysis
Study NCT02983955 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: UPnRIDE Powered Wheelchair
Description: The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
Study NCT05051241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
Study NCT04108884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App measurement
Description: App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations